Extra-corporeal treatments like dialysis, and cardiopulmonary bypass, involve the circulation of the patient's blood supply through a machine. The patient's immune system treats the machine as a large, unwanted foreign body; the resulting inflammatory response contributes to a range of serious complications.
Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of normal.
Cardiopulmonary bypass maintains blood circulation and oxygenation during open heart surgery, but drives up patients' risk of respiratory, hemotological and neurological complications. With its proprietary H-Guard™ biotechnology, Invizius is addressing the side effects of dialysis and other extra-corporeal treatments.
The business is a spin-out from world-class research carried out at the University of Edinburgh, Scotland, and has been funded by Scottish Enterprise's prestigious High-Growth Spinout Programme. Mercia Asset Management is lead investor.